Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT06345534 Recruiting - Cancer, Breast Clinical Trials

FAST-FORWARD vs HAI5

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

Randomized comparison between the FAST-FORWARD schedule and the HAI5 schedule for breast cancer radiotherapy in 5 fractions.

NCT ID: NCT06344793 Recruiting - Breast Cancer Clinical Trials

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Start date: May 20, 2023
Phase:
Study type: Observational

A multi-center, real world study to evaluate the clinical outcomes between initial CDK 4/6 Inhibitor plus endocrine therapy and initial chemotherapy in HR positive, HER2 negative unresectable or metastatic breast cancer.

NCT ID: NCT06344780 Recruiting - Breast Cancer Clinical Trials

Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Start date: May 20, 2023
Phase:
Study type: Observational

A multi-center, real world study to evaluate the clinical outcomes and safety of Abemaciclib, Palbociclib or Dalpiciclib combined with endocrine therapy as first-line treatment in HR Positive, HER2 Negative unresectable or metastatic Breast Cancer.

NCT ID: NCT06343987 Recruiting - Clinical trials for Metastatic Breast Cancer

The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity

Start date: February 19, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment. The aim of the study is to assess the feasibility and metabolic efficacy of a 12-week physical activity program in this patient group. The hypothesis is that improving metabolic health through physical activity can optimize cancer care. Participants will randomized 2:1 to either a physical activity program or care as usual.

NCT ID: NCT06343948 Recruiting - Clinical trials for HR+HER2- Breast Cancer

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Start date: April 24, 2024
Phase: Phase 3
Study type: Interventional

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy.

NCT ID: NCT06343181 Recruiting - Clinical trials for Metastatic Breast Cancer

A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer

Start date: October 3, 2022
Phase:
Study type: Observational

Qualitative observational study with the aim to explore medication adherence in a sample of patients with metastatic breast cancer. Patients with metastatic breast cancer receiving or having received oral oncologic therapy, and attending the Division of Medical Senology at the European Institute of Oncology, will be included and enrolled in this research project."

NCT ID: NCT06342037 Recruiting - Clinical trials for Metastatic Breast Cancer

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

TONIC-3
Start date: June 12, 2024
Phase: Phase 2
Study type: Interventional

This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.

NCT ID: NCT06341894 Recruiting - Early Breast Cancer Clinical Trials

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Start date: November 17, 2023
Phase: Phase 2
Study type: Interventional

The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive, HER2-negative Early Breast Cancer.

NCT ID: NCT06341842 Recruiting - Breast Cancer Clinical Trials

Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity

PROTECT
Start date: October 19, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab. The study aims to describe the efficacy for dapagliflozin as compared to standard of care. Participants will be recruited in participating centers, where they are planning on starting (neo-) adjuvant ACT-based chemotherapy and/or trastuzumab for stage I-III breast cancer.

NCT ID: NCT06341621 Recruiting - Breast Cancer Clinical Trials

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Rainbow
Start date: April 2, 2024
Phase: Phase 3
Study type: Interventional

This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in ER+/HER2-endocrine-sensitive breast cancer with 1-3 positive lymph nodes receiving extended (3 year) adjuvant abemaciclib